Research programme: antibacterials - Bayer

Drug Profile

Research programme: antibacterials - Bayer

Alternative Names: 6-Aminouracil-DNA polymerase inhibitors research programme - Bayer; Antibacterials research programme - Bayer; DNA polymerase inhibitors research programme - Bayer; Phe-RS inhibitors research programme – Bayer; Phenylalanyl-tRNA synthetase inhibitors research programme – Bayer

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer GeneData
  • Class Sulfonamides
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 16 Mar 2005 A preclinical study has been added to the Bacterial Infections pharmacodynamics and antimicrobial activity sections
  • 14 Jul 2003 This programme is still in active development
  • 21 Sep 2001 Preclinical development for Bacterial infections in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top